4-aminopyridine for faster skin wound healing
Official title: 4-aminopyridine for Skin Wound Healing
Run by University of Arizona · NCT06333171 · Data updated 2026-11-12
This trial will see if 4-aminopyridine helps small skin wounds heal faster in healthy adults aged 18–70.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | University of Arizona Academic / other |
| Locations | 1 site (Tucson, Arizona) |
| Status | Recruiting |
| Started | September 2025 |
| Main results expected | September 2027 |
| Study ends | March 2028 |
| Registry record updated | September 3, 2025 |
| Trial ID | NCT06333171 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are otherwise healthy adults aged 18–70 with small wounds of the axilla or upper inner arm expected to heal without surgical closure, who can give informed consent and attend follow-up visits.
✕Probably not a fit
People with prior neurological disorders (like MS or stroke), a history of seizures, known hypersensitivity to 4-aminopyridine, current use of aminopyridine drugs, suspected renal impairment, or complex chronic wounds are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This Phase 2 interventional study compares 4-aminopyridine (4-AP) to a placebo in otherwise healthy adult volunteers with small skin wounds that are expected to heal by secondary intention. Participants will receive either 4-AP or placebo and return for scheduled follow-up visits to monitor wound closure and collect clinical and cellular measures of tissue repair. The rationale is based on animal data showing accelerated healing and increased regenerative markers with 4-AP, and the study aims to translate those findings into humans. Safety, tolerability, and objective wound-healing endpoints will be tracked over the treatment period.
Why it matters
Potential benefit: If successful, 4-aminopyridine could speed healing of uncomplicated skin wounds, potentially reducing healing time and related complications.
How similar studies have gone: Animal studies demonstrated striking improvements in wound closure and regenerative markers with 4-AP, but human data for wound healing are limited and this represents an early-phase human test.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Otherwise healthy adult patients without skin conditions effecting the skin of the axilla or upper inner arm. * Cognitive ability to evaluate wound healing, report sensory and motor deficit during examination. * Eligible for standard of care plan for wound closure by secondary intention (normal healing without intervention). * Adults subject aged 18-70 * Ability to give written informed consent. * Capable of safely coming in for follow up visits on all scheduled appointments. Exclusion Criteria: * History of multiple sclerosis, stroke or any other diagnosed neurological disorder * History of hypersensitivity to AMPYRA® or 4-aminopyridine * Current use of aminopyridine medications, including other compounded 4-AP * Suspected renal impairment based on the Choyke questionnaire. * History of difficult compliance with timely follow up * Patients outside the age range * Unable to provide informed consent. * Patients with a known history of a seizure disorder (4-AP overdose can, in selected cases, result in limited seizure activity). * Patients with a concomitant traumatic brain injury. * Patients unable to communicate. * Patients unwilling to complete the study requirements. * Patients currently taking organic cat-ion transporter 2 (OCT2) inhibitors, e.g. Cimetidine. * Pregnancy, breastfeeding or incarcerated individuals. * Non-English speaking * Patients unable or unwilling to take calibrated (with gauge) photographs of their wounds
Where it's running
-
University of Arizona
Tucson, Arizona, United States Recruiting
Study contacts
- Principal investigator: John Elfar, MD — University of Arizona
- Study coordinator: Andrea Horne
- Email: ahh@arizona.edu
- Phone: 520-626-6456
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PowerHeal Bioelectric Bandage for infected open wound recovery
This tests whether the PowerHeal™ Bioelectric Bandage helps adults with infected traumatic wounds heal faster and clear infection better than standard dressings.
-
WounDx device to help guide delayed closure of large traumatic limb wounds
This pilot tests whether the WounDx device can help surgeons decide when delayed closure will successfully heal large traumatic extremity wounds in adults.
-
Tissue Repair Gel for treating Venous Leg Ulcers
This study is testing a new gel to see if it helps people with stubborn leg ulcers heal better when used with standard treatment compared to standard treatment alone.
-
Tracking the healing of chronic venous leg ulcers with a special foam dressing
This study is testing a special foam dressing to see if it helps people with chronic venous leg ulcers heal better over six weeks.
-
Tracking the healing of chronic wounds with a special dressing
This study is testing a special dressing called Mepilex Up to see if it helps people with chronic wounds, like venous leg ulcers and diabetic foot ulcers, heal better over six weeks.
-
Using Oasis ECM to treat donor site wounds
This study is testing if a new treatment called Oasis ECM can help heal donor site wounds better than regular wound care for people over 16 in the UK.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.